Novartis Ag

Michel Faure

Paul A Renhowe

Paul Andrew Barsanti

David Duhl

Tinya Abrams

Annette Olga Walter

Carla C Heise

Nguyen Tan

Eleni Venetsanakos

The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.

Kinesin inhibitors as cancer therapeutics

The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.

Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma

Growing community of inventors

Oakland, CA, United States of America

Michel Faure